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PCRa b s t r a c t
The CYD tetravalent dengue vaccine candidate is being evaluated for protective efﬁcacy against symp-
tomatic dengue in Phase 3 efﬁcacy trials. The laboratory test algorithm to conﬁrm dengue cases was eval-
uated prior to Phase 3 trials. During a Phase 2 trial in Latin America a dengue epidemic occurred in the
study countries. A total of 72 suspected dengue cases were reported and assessed: virological conﬁrma-
tion comprised qRT-PCR methods and a commercial ELISA kit for NS1 protein (Bio-Rad). The qRT-PCR
included a screening assay targeting a conserved dengue region of the 30-UTR (dengue screen assay) fol-
lowed by 4 individual serotype assays targeting the conserved dengue NS5 genomic region (WT dengue
qRT-PCR assays). The NS1 and WT dengue qRT-PCR were endpoint assays for protocol virological conﬁr-
mation (PVC). Of the 72 suspected cases, 14 were PVC. However, a unique pattern of dengue qRT-PCR
results were observed in 5 suspected cases from Honduras: the dengue screen qRT-PCR assay was posi-
tive but WT dengue qRT-PCR and NS1 Ag ELISA were negative. To investigate these observations, addi-
tional molecular methods were applied: a SYBR Green-based RT-PCR assay, sequencing assays
directed at the genome regions covered by the WT dengue qRT-PCR, and a modiﬁed commercial dengue
RT-PCR test (Simplexa™ Dengue, Focus Diagnostics). The exploratory data conﬁrmed these additional
cases as dengue and indicated the serotype 2 WT dengue qRT-PCR assay was unable to detect a circulat-
ing Latin American strain (DENV-2/NI/BID-V608/2006) due to a sequence variation in the isolate. The
Simplexa Dengue RT-PCR test was able to detect and serotype dengue. Based on these ﬁndings an
updated molecular test algorithm for the virological conﬁrmation of dengue cases was developed and
implemented in the Phase 3 efﬁcacy trials.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).Introduction
The dengue virus is a member of the Flavivirus (FV) genus,
which also includes the yellow fever (YF) virus [1]. Dengue disease
is caused by any of four dengue virus serotypes (serotypes 1–4),
and is transmitted primarily by the Aedes aegypti mosquito [2].
Most dengue virus infections are asymptomatic, but clinical man-
ifestations may range frommild febrile illness to severe and poten-
tially fatal disease [2].Dengue disease is endemic in the Caribbean, Central and South
America, and Mexico, where the number of cases has increased
dramatically in recent decades [3]. In 2011, nearly 1.1 million cases
of dengue disease, including over 19,000 cases of severe dengue
and more than 700 dengue-related deaths, were reported in Latin
America [4].
No speciﬁc treatment exists for dengue disease, and preventive
measures, which include mosquito control and personal protection
from bites, have limited effectiveness. A recombinant, live-attenu-
ated, tetravalent dengue vaccine (CYD-TDV; Sanoﬁ Pasteur, Lyon,
France) is under development containing four recombinant viruses
(CYD-1–4) [5,6]. The CYD-TDV is currently in large scale Phase 3
efﬁcacy trials in SE Asia and Latin America for prevention of symp-
tomatic dengue. The evaluation of suspected dengue cases and
diagnostic algorithms was assessed prior to Phase 3 in studies per-
formed in endemic areas, as part of ensuring a robust standardized
case deﬁnition for application in the Phase 3 efﬁcacy studies.
128 M. Boaz et al. / Trials in Vaccinology 3 (2014) 127–133Virological conﬁrmation is performed with a two-step quantitative
reverse transcriptase polymerase chain reaction (qRT-PCR) algo-
rithm consisting of an initial dengue screen qRT-PCR with subse-
quent serotyping by four serotype-speciﬁc wild-type (WT)
dengue qRT-PCR assays, and/or with antigenic detection using
NS1 Ag ELISA. In one such preparatory study, conducted primarily
to evaluate the safety and immunogenicity of CYD-TDV in 9 to 16-
year-olds in Latin America [7], unique observations were made
with the protocol diagnostic algorithm versus previous observa-
tions from studies in SE Asia. The objective of this paper is to
describe these observations in the Latin American Phase 2 trial,
the subsequent tests performed to further characterize the circu-
lating dengue cases, and subsequent adaptation of the diagnostic
algorithm used for virological conﬁrmation of dengue cases in clin-
ical trials.Materials and methods
Study design and sample collection
This study was a randomized, observer-blind (ﬁrst and second
injections), single-blind (third injection), controlled trial conducted
in Colombia, Honduras, Mexico, and Puerto Rico (National Clinical
Trials Identiﬁer: NCT00993447) [7]. Healthy volunteers aged 9–
16 years were randomized 2:1 to receive three subcutaneous injec-
tions of CYD-TDV or a control (placebo [0.9% NaCl] as the ﬁrst and
second subcutaneous injections and a tetanus/diphtheria/acellular
pertussis [Tdap] vaccine as the third intramuscular injection).
Injections were administered at 0, 6, and 12 months.
The study was conducted in accordance with the Declaration of
Helsinki (Edinburgh, October 2000), Good Clinical Practice, Inter-
national Conference on Harmonization guidelines and national
and local ethical requirements. Written informed consent was
obtained from participants and/or a parent or legal guardian.
Symptomatic dengue cases were detected using surveillance of
febrile episodes deﬁned in alignment with theWHO case deﬁnition
(e.g., temperature P38 C on at least 2 consecutive days with a
suspicion of dengue disease) [7].
Standard tests for virological conﬁrmation of dengue
The tests performed to virologically conﬁrm suspected dengue
cases were those applied across all CYD vaccine studies and
included validated qRT-PCR assays, and a commercially available
enzyme-linked immunosorbent assay (ELISA) against the dengue
non-structural protein 1 (NS1) antigen (Platelia™, Biorad Laborato-
ries, Marnes-La-Coquette, France). The qRT-PCR testing for all sus-
pected dengue cases is performed centrally at the sponsor’s Global
Clinical Immunology laboratory in a GCLP-like environment, with
laboratory personnel blinded to the study groups, and include a
screening assay targeting a conserved dengue region of the 30-
UTR (Dengue screen assay; adapted from [8]), followed by four
individual serotype assays that utilize speciﬁc primers and probes
for each dengue serotype targeting conserved dengue NS5 genomic
regions (WT dengue qRT-PCR assays). The NS1 and WT dengue
qRT-PCR were endpoint assays for protocol virological conﬁrma-
tion (PVC) (Fig. 1).
Additional tests to characterize virological dengue
Additional testing conducted post hoc using molecular methods
to further characterize the dengue cases included a SYBR Green-
based RT-PCR assay, sequencing assays directed at the dengue
genomic regions covered by the dengue qRT-PCR assays, and a
modiﬁed commercial dengue RT-PCR test (Simplexa™ Dengue,Focus Diagnostics, CA, US). These additional tests were performed
by laboratory personnel blinded to the study groups, in samples
from suspected dengue cases that had consented to tests for
research purposes, and that fulﬁlled the following criteria: a den-
gue screen qRT-PCR positive result according to the protocol deﬁ-
nition (PLLOQ), or that had a detectable result which could not be
quantiﬁed (>LOD). As an internal control, one sample that was NS1
antigen positive with no RNA quantiﬁed by the Dengue screen qRT-
PCR was included in testing. The RNA used in these experiments
were from the extractions performed from subject sera for the
standard protocol virological testing described above, except for
the Simplexa Dengue testing, which used freshly extracted RNA
from different aliquots of the same sera.
The SYBR Green-based RT-PCR assay was performed by substi-
tuting SYBR Green in place of the probes. This method, using the
serotype speciﬁc primers from the WT dengue qRT-PCR assays,
permits the SYBR Green dye to intercalate into any double-
stranded DNA, emitting a ﬂuorescent signal detectable by the
thermalcycler.
To assess changes to the assay-speciﬁc genomic regions,
sequencing of the NS5 regions was performed on an ABI 3130XL
system (Life Technologies, CA, USA), using the amplicons produced
by each WT dengue qRT-PCR assay. The results from the sequenc-
ing reactions were compared to 950 dengue 2 sequences from
Latin America, the Caribbean and Asia retrieved from the National
Center for Biotechnology Information (NCBI) database using a Basic
Local Alignment Search Tool (BLAST). The commercial dengue RT-
PCR test (Simplexa Dengue, Focus Diagnostics) was performed fol-
lowing an adapted version of the manufacturer’s instructions.
A phylogenetic tree was conducted using FastTree software
(Lawrence Berkeley National Lab, US) from a multiple sequence
alignment performed with the Muscle algorithm [9]. The phyloge-
netic tree was customized using Dendroscope software (University
of Tubingen, Germany). The NS5 coding sequence corresponding to
nucleotides 7548–10,247 of the dengue 2 isolate: DENV-2/NI/BID-
V608/2006 (accession number EU596483.1) was aligned for den-
gue serotype 2 isolates obtained in Latin America and the
Caribbean.Results
Protocol-deﬁned virological test results
Of subjects with suspected dengue, 14 were positive by virolog-
ical conﬁrmation (PVC) according to protocol endpoint assays
although 5 could not be serotyped by RT-PCR (Table 1, subjects
#1–14 and 2, 7, 8, 13, 14, respectively). A further 5 samples had
virological test results indicative of a recent Dengue infection but
were positive in the Dengue screen qRT-PCR only and not other
protocol virological testing (Table 1, subjects #15–19).Exploratory analysis
Additional molecular methods were applied to serotype the
remaining 5/14 PVC cases and to assess the 5 additional samples
that were positive in the Dengue screen qRT-PCR only. In addition,
7/9 of the serotyped PVC cases were available for exploratory test-
ing and were included to help assess these additional molecular
methods (Fig. 2).
Seven of the 10 non-serotyped qRT-PCR positive cases were
from Honduras (Table 1, subjects #13–19) suggesting that circulat-
ing Honduran strains exhibited sequence differences that pre-
vented detection in the standard in-house serotyping assay (WT
dengue qRT-PCR assay). To assess the potential impact of sequence
changes in the probe region, we tested these samples with a SYBR
Per‐protocol endpoint assays
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Fig. 1. Protocol virological testing algorithm for acute samples from suspected dengue cases.
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standard in-house assay. This method was able to identify and
serotype 5 of the previously untypable samples as serotype 2
(Table 1, subjects #13–17). We followed these studies with Sanger
sequencing of the NS5 region, and were able to serotype 4/5
remaining untyped cases: serotype 2 was determined in 2 cases
(Table 1, subjects #18–19), and serotype 4 in the 2 other cases
(Table 1, subjects #7–8). The ﬁnal remaining untyped sample
was determined by testing with the Simplexa dengue RT-PCR
(Table 1, subject #2).
The NS5 sequencing data highlighted why the standard serotyp-
ing assay was unable to detect 7 of the dengue 2 samples (Table 1,
subjects #13–19). A BLAST search indicated these cases corre-
sponded to a Nicaraguan dengue 2 isolate: DENV-2/NI/BID-V608/
2006 (accession number EU596483.1). This isolate exhibited a
non-synonymous sequence variation at position 8807 (G?A) com-
pared to the standard in-house serotyping assay dengue 2 probe
region (50-TGGAAGTCGGCACGTGA-30). A genetic dendrogram of
this isolate compared to other dengue 2 isolates obtained from
Latin America and the Caribbean is shown in Fig. 3. This isolate is
similar to other Latin American or Caribbean strains but not similar
to Asian strains at position 8807. Fully annotated dengue 2
sequences (n = 950) were retrieved from the NCBI database cover-
ing Latin America, the Caribbean and Asia; most Latin American/Caribbean strains exhibit an A (96%) whereas Asian strains have
a G (98%) at position 8807. This association between A at position
8807 in Latin American dengue 2 isolates and the lack of typing by
the in-house serotyping assay was conﬁrmed in samples
sequenced from another Latin American CYD-TDV study that could
not be typed (isolate accession numbers GQ868557.1, GU131955.1,
HQ999999.1 and JN819422.1, unpublished data). In CYD-TDV stud-
ies conducted in Asia we have been able to type dengue using the
in-house serotyping assay and have not observed similar clusters
of dengue 2 as in the present study that are untypable ([10] and
data not shown).
Of the two newly conﬁrmed serotype 4 cases (Table 1, subjects
#7–8) a BLAST search of the NS5 sequence indicated both
corresponded to a Colombian dengue 4 isolate: DENV-4/CO/BID-
V3412/2005 (accession number GQ868585.1). Although this
isolate had a sequence variation at position 9977 (A?G) versus
the standard in-house serotyping assay’s dengue 4 probe region
(50-CAAAGTGTGGAACAGAGTG-30), it seems the low concentration
of virus in the sample may have led to a lack of conﬁrmation in
the standard assay rather than sequence variation, as this strain
was detected in one subject with a viremia level near the assay
limits (Table 1, subject #7). Additional sequence variations were
also observed in some of the serotyped cases that did not result
in loss of detection in the standard in-house serotyping assay.
Table 1
Protocol and exploratory results of the suspected dengue case testing.
Subject info Protocol virological testing Exploratory virological testing Virological conﬁrmation
# Treatment Dengue screen
qRT-PCR
WT dengue
qRT-PCR
NS1 Ag SYBR
Green
Sequencing Simplexa According to
protocol
According to
exploratory testing
Colombia
1 CYD-TDV Positive Den 1 Positive Den 1 Den 1 Den 1 Y Y
2 CYD-TDV <LLOQ <LOD Positive <LOD Negative Den 1 Y Y
3 CYD-TDV Positive Den 3 Positive Den 3 Den 3 Den 3 Y Y
4 CYD-TDV Positive Den 3 Positive Den 3 Den 3 Den 3 Y Y
5 Control Positive Den 3 Positive Den 3 Den 3 Den 3 Y Y
6 Control Positive Den 3 Positive Den 3 Den 3 Den 3 Y Y
7 Control Positive <LLOQ* Positive <LOD Den 4 Den 4 Y Y
8 Control Positive <LOD Positive <LOD Den 4 Den 4 Y Y
Mexico
9 Control Positive Den 1 Positive NA NA NA Y NA
Puerto Rico
10 CYD-TDV Positive Den 1 Positive NA NA NA Y NA
Honduras
11 CYD-TDV Positive Den 1 Negative Den 1 Den 1 Den 1 Y Y
12 Control Positive Den 1 Positive Den 1 Den 1 Den 1 Y Y
13 Control Positive <LOD Positive Den 2 Den 2 Den 2 Y Y
14 Control Positive <LOD Positive Den 2 Den 2 Den 2 Y Y
15 Control Positive <LOD Negative Den 2 Den 2 Den 2 N Y
16 Control Positive <LOD Negative Den 2 Den 2 Den 2 N Y
17 CYD-TDV Positive <LOD Negative Den 2 Den 2 Den 2 N Y
18 Control Positive <LOD Negative <LOD Den 2 Den 2 N Y
19 CYD-TDV Positive <LOD Negative <LOD Den 2 <LOD N Y
* WT qRT-PCR for Den 4. LOD = Limit of detection. LLOQ = Limit of quantitation.
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clinical trials, the Simplexa dengue RT-PCR was also used to assess
the non-serotyped cases. This assay, which for serotype 2 incorpo-
rates primers within NS3, was able to serotype 8 of the 9 samples
that were not serotyped by the standard in-house serotyping assay
(Table 1, subjects # 2, 8, 13–18). These tests were performed using
freshly extracted RNA from the original serum samples. The single
sample that was not detected with the Simplexa dengue RT-PCR
was retested with the Simplexa dengue RT-PCR, as well as with
the Dengue screen qRT-PCR, and was not detected in either assay
(Table 1, subject #19).
As a control, all of the exploratory assays were performed con-
currently in PVC cases serotyped by the standard WT dengue qRT-
PCR assay (Table 1, subjects # 1, 3–6, 11–12). Results across the
nucleic acid based assays were mostly concordant: the NS5 dengue
sequencing detected all samples, the Simplexa dengue RT-PCR
detected all but one, while the SYBR Green assay was slightly less
consistent (Table 1).
Discussion
The observation in this Latin American Phase 2 study of a clus-
ter of suspected dengue cases that had a positive Dengue screen
qRT-PCR result but could not be serotyped by the standard in-
house serotype-speciﬁc qRT-PCRs prompted further virological
assessment. Our analyses suggest constraints in the original end-
point assays due to sequence differences between these isolates
and the qRT-PCR probe led to the non-serotyping of these cases.
Although the endpoint serotyping WT dengue qRT-PCR assay did
not detect some dengue strains, the Dengue screen qRT-PCR assay
used as the ﬁrst step of the molecular algorithm was capable of
detecting the dengue strains encountered. It is important to note
that although applied in this clinical study as a screening assay
not an endpoint assay, the dengue screen qRT-PCR is expected to
be dengue speciﬁc as it is based upon highly conserved dengue
speciﬁc sequences of the 30 UTR region. Furthermore, the method
behind this assay has been demonstrated to be speciﬁc for dengue
virus versus other ﬂaviviruses [8].In reality it is not unexpected that some strains were not
detected in the serotyping assays, despite targeting highly con-
served NS5 regions. The dengue virus is an RNA virus that repli-
cates via an error prone RNA polymerase with high mutation
rates [11]. This phenomenon has been observed with another
RNA virus, inﬂuenza, where a mutation prevented RT-PCR subtyp-
ing [12] of isolates. Similar clusters of untypable dengue RNA posi-
tive samples have not been observed in prior CYD dengue studies,
including those conducted in Asia [10,13–14], where this Nicara-
guan dengue 2 isolate and other Latin American strains bearing
the sequence variation do not appear to circulate.
The majority of the cases involving this particular Nicaraguan
dengue 2 strain seen in our study were also not detected by the
NS1 Ag ELISA (the second type of endpoint assay adopted in the
initial virological algorithm). This may be related to the level of
NS1 Ag circulating in these individuals as patients with dengue
caused by serotype 2 have been observed to have lower levels of
serum NS1 Ag compared with serotype 1 [15]. However, lower
serotype 2 identiﬁcation by NS1 Ag is not apparent in all studies
[16–17], and some samples have been observed that are positive
for NS1 antigen but not dengue RNA [18].
Our observations have implications for the molecular test algo-
rithm used to virologically conﬁrm and serotype dengue disease,
not only for the development of the CYD vaccine candidate, but
also for other vaccine developers, and for the dengue ﬁeld in gen-
eral. The use of RT-PCR assays for virological conﬁrmation and
serotyping of dengue is recommended by the WHO [19] and has
been in widespread use by the ﬁeld since the seminal paper from
Lanciotti et al. [20]. The performance of the Dengue screen qRT-
PCR assay and of the commercially available Simplexa dengue
RT-PCR assay was encouraging. We implemented the Dengue
screen qRT-PCR in our original algorithm to screen for dengue
RNA positive samples prior to serotyping to facilitate the testing
workload, given the tens of thousands of samples to be tested dur-
ing the Phase 3 efﬁcacy trials. In addition, these current data sug-
gest the use of differential target regions within the molecular
assay algorithm is also beneﬁcial for detection. The Simplexa Den-
gue RT-PCR assay was able to serotype all apparent Dengue screen
Samples submied 
to exploratory tesng
7 serotyped PVC 
cases included as 
controls
Results of per-protocol endpoint assays
Dengue screen
RT-PCR 
+-
WT dengue RT-PCR
DENV-1
WT dengue RT-PCR
DENV-2
WT dengue RT-PCR
DENV-3
WT dengue RT-PCR
DENV-4
-
-
-
-
N=18
N=5*+
+
+
+
N=4
N=0
N=0
N=1
This sample was 
NS1Ag+
N=3
N=4
N=1
9 were 
negave in all 4 WT 
RT-PCRs. Of which:
4 were NS1Ag+
5 were NS1Ag-
N=9
*2 samples could not be tested due to a lack of informed consent for exploratory tesng
Fig. 2. Provenance of 17 samples selected for additional molecular testing.
Fig. 3. Phylogenetic tree of studied sequences within Latin American and Caribbean strains of serotype 2 joined by maximum likelihood method. The tree is based on NS5
regions (nt8802-8818) of the selected strains. Each strain is abbreviated by its serotype, year of isolation, country of isolation and region, genotype and Genbank accession
number. Blue strains indicate Latin American strains, and the isolated strain is highlighted in yellow. The variability distance scale is shown. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Boaz et al. / Trials in Vaccinology 3 (2014) 127–133 131qRT-PCR positive samples. The ability to serotype diverse strains is
critical for monitoring circulating virus and to assess serotype-spe-
ciﬁc protective efﬁcacy afforded by vaccination. The ability of the
Simplexa Dengue RT-PCR assay to serotype diverse strains hasbeen demonstrated in Asian and Latin American settings in the
ﬁeld [21–22].
Given the encouraging results seen here with the Dengue screen
qRT-PCR coupled with the Simplexa Dengue RT-PCR assays in our
Fig. 4. Protocol virological testing algorithm for suspected dengue cases in the Phase 3 efﬁcacy trials.
132 M. Boaz et al. / Trials in Vaccinology 3 (2014) 127–133hands, we extended our evaluation beyond the present study using
a larger, more diverse set of samples from suspected dengue cases
in SE Asia and Latin America. The assays’ performance was con-
ﬁrmed (data not shown), and the use of the Simplexa Dengue
RT-PCR assay at Sanoﬁ Pasteur was subsequently validated accord-
ing to industry guidelines [23–24]. Collectively, these ﬁndings
enabled us to modify the molecular test algorithm for the virolog-
ical conﬁrmation of dengue infection among suspected cases
occurring in dengue vaccine studies (Fig. 4). The modiﬁed algo-
rithm incorporates the Dengue screen qRT-PCR assay as an end-
point assay in addition to the dengue NS1 Ag ELISA endpoint
assay and uses the Simplexa Dengue RT-PCR assay for serotyping.
This algorithm is being applied at our central testing facility as part
of efﬁcacy evaluations for the two ongoing CYD vaccine efﬁcacy tri-
als in SE Asia and Latin America.Conﬂict of interest
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